Reactive oxygen species a double-edged sword for mesothelioma

Serena Benedetti, Barbara Nuvoli, Simona Catalani and Rossella Galati _

PDF  |  HTML  |  How to cite

Oncotarget. 2015; 6:16848-16865. https://doi.org/10.18632/oncotarget.4253

Metrics: PDF 2657 views  |   HTML 4789 views  |   ?  


Serena Benedetti1,*, Barbara Nuvoli2,*, Simona Catalani1, Rossella Galati2

1Department of Biomolecular Sciences, University of Urbino “Carlo Bo”, Urbino, Italy

2Molecular Medicine Area, Regina Elena National Cancer Institute, Rome, Italy

*These authors have contributed equally to this work

Correspondence to:

Rossella Galati, e-mail: [email protected]

Keywords: reactive oxygen species, mesothelioma, cell trasformation, cell proliferation, therapy

Received: April 20, 2015     Accepted: May 29, 2015     Published: June 10, 2015


It is well known that oxidative stress can lead to chronic inflammation which, in turn, could mediate most chronic diseases including cancer. Oxidants have been implicated in the activity of crocidolite and amosite, the most powerful types of asbestos associated to the occurrence of mesothelioma. Currently rates of mesothelioma are rising and estimates indicate that the incidence of mesothelioma will peak within the next 10–15 years in the western world, while in Japan the peak is predicted not to occur until 40 years from now. Although the use of asbestos has been banned in many countries around the world, production of and the potentially hazardous exposure to asbestos is still present with locally high incidences of mesothelioma. Today a new man-made material, carbon nanotubes, has arisen as a concern; carbon nanotubes may display ‘asbestos-like’ pathogenicity with mesothelioma induction potential. Carbon nanotubes resulted in the greatest reactive oxygen species generation. How oxidative stress activates inflammatory pathways leading to the transformation of a normal cell to a tumor cell, to tumor cell survival, proliferation, invasion, angiogenesis, chemoresistance, and radioresistance, is the aim of this review.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4253